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The estimated prevalence of oral leukoplakia is worldwide approximately 2%, with an annual malignant
transformation rate of approximately 1%. The aim of the present study was to evaluate the possible con-
tribution of ploidy measurement to the prediction of the clinical course, in a well deﬁned cohort of
patients with oral leukoplakia. Ploidy was measured by both ﬂow cytometry (FCM-DNA) and image
cytometry (ICM-DNA) and we focussed on the comparison of the two different techniques to determine
ploidy. A total of 41 patients have been included, with a mean age of 59 years (range 36–78 years). With
FCM-DNA, three lesions were aneuploid, with ICM-DNA, 19 lesions were aneuploid. DNA ploidy was com-
pared with clinicopathological and patients parameters. There were no statistically signiﬁcant differences
between DNA ploidy and any patient factor with both FCM-DNA and ICM-DNA. Using FCM-DNA, DNA
aneuploid lesions showed statistically signiﬁcant more dysplasia (p = 0.04) than diploid lesions. Further-
more, DNA aneuploid lesions were more frequently encountered at high-risk locations (p = 0.03) as being
determined with FCM-DNA. These relations were not found when DNA ploidy was determined with ICM-
DNA.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Leukoplakia is deﬁned as ‘a white plaque of questionable risk
having excluded (other) known diseases or disorders that carry
no increased risk for cancer’.1 The estimated prevalence of oral leu-
koplakia worldwide is approximately 2%,2 with an annual malig-
nant transformation rate into oral squamous cell carcinoma
(OSCC) of approximately 1%.3 Several factors are known to be asso-
ciated with an increased risk of malignant transformation of leuko-
plakia, e.g. homogeneity and size of the lesion.3–5 At present, the
best predictor is the presence of epithelial dysplasia. Nevertheless,
some dysplastic lesions may remain unchanged or resolve over
time.6,7 A limitation of dysplasia grading is its relative subjective
character, indicated by a high inter- and intra-examiner variability
in the assessment of dysplasia.8–11
Another suggested parameter of prognostic value could be DNA




sevier OA license.have shown a higher risk of malignant transformation13 and DNA
aneuploid gastric cancer has an unfavourable prognosis compared to
DNA diploid cancer.14 Recent DNA ploidy studies of dysplastic oral le-
sions have suggested thatDNAaneuploid lesions carry ahigher risk for
OSCC progression.15–18 The DNA ploidy status can be measured by
either ﬂow cytometry (FCM-DNA) or image cytometry (ICM-DNA).
The aim of the present study was to evaluate the possible differ-
ence between DNA ploidy measurement using either FCM-DNA or
ICM-DNA, in a well deﬁned cohort of patients with oral leukopla-
kia. This study is a continuation of the study of Bremmer et al.18
Relations between DNA ploidy and the histopathological grading
and other clinical parameters, such as gender, smoking habit, alco-
hol consumption, homogeneity, size and location of the lesion
were investigated. Moreover, all leukoplakias were classiﬁed by
the OL-classiﬁcation and staging system.3Material and methods
Patients
For the purpose of this retrospective study, 87 patients were se-
lected on the basis of biopsied leukoplakias with sufﬁcient material
for histopathological grading as well for DNA ploidy measurement,
Table 2
Site distribution of 41 patients with leukoplakia.
Oral subsite Number of patients
Tongue (dorsal and lateral surfaces) 10
Floor of mouth 7
Hard palate 3
Cheek mucosa 5
Upper and lower alveolus and gingiva 4
Multiple sites 12
Total 41
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ferred to the Department of Oral and Maxillofacial Surgery at
VUmc/ACTA, Amsterdam, and the biopsies were taken between
2003 and 2010. Patients with an (previous or concomitant) OSCC
were excluded (n = 8). Also, patients in whom DNA ploidy could
not be determined were excluded (n = 38). A total of 41 out of 87
patients fulﬁlled all inclusion criteria: 20 men and 21 women, with
a mean age of 59 years (range 36–78 years). Nine patients in this
cohort overlapped between this study and the study by Bremmer
et al.18 The smoking habits and alcohol consumption of these pa-
tients are shown in Table 1.
Clinically, a distinction was made between homogenous and
non-homogeneous leukoplakia. There were 28 patients with a
homogeneous leukoplakia and 13with the non-homogeneous type.
The location of leukoplakia was speciﬁed according to six sites: ton-
gue, ﬂoor of mouth (FOM), hard palate, buccal mucosa, upper and
lower alveolus and gingiva, and multiple sites (Table 2). All this
information was extracted from the patient ﬁles.
The size, presence and grade of epithelial dysplasia were
determined by means of the OL-classiﬁcation and staging system
(Table 3).3 Twenty-three leukoplakias were L1, 10 cases were L2
and seven were L3. Size could not be determined in one case. There
were 23 excisional and 18 incisional biopsies performed. All biop-
sies were revised on haematoxylin and eosin (H&E) stained sections
by the same investigators (EREAB/EB), a joint consensus was made
for the cases that were graded differently. Severe dysplasia (P2)
was diagnosed in six biopsies, mild-moderate dysplasia (P1) in 14
biopsies, while dysplasia was absent (P0) in 21 biopsies. The biopsy
on which the histological grading was done, was also used for DNA
ploidy determination.
Initial and follow-up management included surgical excision,
CO2-laser therapy or observation. All patients were advised to quit
smoking.19 The follow-up period ranged from 12 to 87 months
with a median of 20 months. The follow-up period started at the
date the biopsy was taken. It ended in case of lost to follow-up,
death, or development of OSCC at the site of oral leukoplakia or
elsewhere in the oral cavity.
The design of this study adheres to the code for proper second-
ary use of human tissue of the Dutch Federation of Biomedical Sci-
entiﬁc Societies (http://www.federa.org).20Tissue processing for FCM-DNA and ICM-DNA
Formalin ﬁxed parafﬁn-embedded tissue specimens, the same
which were used for histopathological grading, were collected from
the pathology archive. Two or three 50 lm sections were cut from
the tissue specimens and nuclear cell suspensions were prepared
according to the Hedley procedure.21 For FCM-DNA, part of the nu-
clear suspension was stained with DAPI (40,6-diamidino-2-pheny-
lindol, Partec Instruments, Muenster, Germany). For ICM-DNA,
cytospins were prepared from the other part by centrifugation of
the specimen for 15 min at 3000 rpm. The cytospins for ICM-DNA
were stained using the Feulgen method according to the consensus
of the European Society for Analytical Cellular Pathology,22 with
minor modiﬁcations. Cytospin preparations were placed in 5 N
HCL for 30 min at 27 C. Hereafter the cytospins were rinsed inTable 1
Distribution of tobacco and alcohol habits among 41 patients with oral leukoplakia.
Gender Patients Tobacco
Smoker Non-smoker
Men 20 12 6
Women 21 14 5
Total 41 26 11distilled water for 5 min, stained with fresh Schiff’s reagent for
45 min, and then washed in running tap water for 15 min. Last,
the cytospin slides were dehydrated and cover slipped.
Measurement of FCM-DNA
The FCM-DNA measurements were done within 3 h after DAPI
staining. For the measurements a Partec Pas II mercury lamp-based
ﬂow cytometer (Partec Instruments) was used. Trout erythrocytes
were used as external control cells. The procedure is described in
detail elsewhere.23
Measurement of ICM-DNA
The DNA content of stained nuclei was measured and analysed
by ICM-DNA according to a published protocol.14,24 The guidelines
of the consensus report of the European Society for Analytical
Cellular Pathology were followed.22 Köhler illumination was ap-
plied, before every ICM-DNA analysis. The camera was switched
on at least 15 min before every measurement to ensure standard-
ised conditions. Images were linearly corrected for shading with
two empty images, namely one illuminated and one dark-current
image.25 The resulting corrected grey values provided a measure
for the local optical density. Segmentation was carried out in a fully
automatic manner.14,24 A ﬁlter was used during measurements to
remove debris and aggregates.
Approximately, 1000 nuclei were measured in a fully automatic
manner. Lymphocytes and ﬁbroblasts were included as internal
DNA diploid controls and were used to calibrate and scale the
DNA histogram. Using classiﬁcation algorithms, round dark con-
dense objects resembling lymphocytes and ellipsoid objects
resembling ﬁbroblasts were automatically identiﬁed. The majority
of remaining debris and aggregates were automatically removed
with another set of classiﬁcation algorithms from the data set.
The resulting DNA histograms were visually inspected. Nuclei,
which should have been removed on the basis of features such as
shape and texture automatically, but were missed by the classiﬁca-
tion algorithms, were removed manually.
In DNA cytometry, nuclear DNA content is measured in relative
units ‘c’, in which the DNA content of normal nuclei is set at 2c. In
this study, the 2c reference value was determined by taking the
mean DNA content measured for nuclei that were identiﬁed as
lymphocytes and ﬁbroblasts. After establishing the 2c reference
value, the histogram was scaled up to 10c with a ﬁxed number
of 256 bins to obtain standardised histograms that cover a wideAlcohol
Unknown Use No-use Unknown
2 10 4 6
2 6 4 11
4 16 8 17
Table 3
Classiﬁcation and staging system for oral leukoplakias (OL-system).
L (size of the leukoplakia)
L1 Size of single or multiple leukoplakias together <2 cm
L2 Size of single or multiple leukoplakias together 2–4 cm
L3 Size of single or multiple leukoplakias together >4 cm
Lx Size not speciﬁed
P (pathology)
P0 No epithelial dysplasia (includes ‘‘no or perhaps mild
epithelial dysplasia’’)
P1 Mild or moderate epithelial dysplasia
P2 Severe epithelial dysplasia
Px Absence or presence of epithelial dysplasia not speciﬁed




Stage 3 L3P0 or L1L2P1
Stage 4 L3P1 or LP2
General rules of the OL-staging system
1. If there is doubt concerning the correct L category to which a particular
case should be allotted, than the lower (i.e. less advanced) category should
be chosen. This will also be reﬂected in the stage grouping
2. In case of multiple biopsies of single leukoplakia or biopsies taken from
multiple leukoplakias the highest pathological score of the various
biopsies should be used
3. For reporting purposes the oral subsite according to the ICD-DA should be
mentioned (World Health Organisation, International Classiﬁcation of
Diseases. Tenth Revision. Application to Dentistry and Stomatology, ICD-
DA, Geneva, 1992)
Table 4
DNA ploidy in leukoplakia using two different methods.
ICM-DNA
FCM-DNA Aneuploid Diploid Total
Aneuploid 2 1 3
Diploid 17 21 38
Total 19 22 41
FCM-DNA = ﬂowcytometry.
ICM-DNA = image cytometry.
638 E.R.E.A. Brouns et al. / Oral Oncology 48 (2012) 636–640range of c values that potentially occur in populations of tumour
nuclei.14
Analysis of DNA histogram FCM-DNA and ICM-DNA
The DNA histograms were analysed using the MultiCycle AV
computer programme (Phoenix Flow Systems, San Diego, CA,
USA), according to a previously described protocol.26 The DNA in-
dex was calculated by dividing the modal channel number of
DNA aneuploid peaks by the corresponding number of the DNA
diploid peak. In case of only one cell cycle, the DNA index was
set at 1.00. All FCM-DNA and ICM-DNA cases were classiﬁed in
two subclasses, based on previous published guidelines as fol-
lows22: DNA diploid (only one cell cycle present) and DNA aneu-
ploid (DNA indexP 1.1).
Statistical analysis
Minimum, maximum, mean, and median values of continuous
variables were calculated. Relevant data were cross-tabulated. Sta-
tistically signiﬁcant relations were tested with the Chi-square test.
The variables age, gender, smoking habit, alcohol consumption,
homogeneity, dysplasia, size of the lesion, location and DNA ploidy
were used. The results were statistically signiﬁcant if the P-value
was less than 0.05. For all statistical analyses, SPSS 17.0 for Win-
dows (SPSS Inc., Chicago, IL, USA) was used.
Results
Ploidy measurement by ﬂow (FCM-DNA) and image cytometry (ICM-
DNA)
In this study, 38 leukoplakias were DNA diploid and three were
DNA aneuploid using FCM-DNA. However, by ICM-DNA, 19
leukoplakias were found to be DNA aneuploid (n.s.) (Table 4). Con-
cordance between FCM-DNA and ICM-DNA was present in two le-
sions which were DNA aneuploid with both methods. However,
one lesion was DNA aneuploid using FCM-DNA, but DNA diploidwith ICM-DNA. Seventeen lesions that were DNA diploid by FCM-
DNA measurement were DNA aneuploid using ICM-DNA.Relation between clinicopathological parameters and ploidy measured
by ﬂow cytometry (FCM-DNA)
All DNA aneuploid lesions (n = 3) showed mild-moderate epi-
thelial dysplasia (P1). In total, 18% of the dysplastic leukoplakias
and 7% of the whole patient group were DNA aneuploid using
FCM-DNA. In contrast to DNA diploid lesions, DNA aneuploid le-
sions always showed dysplasia (p = 0.04) (Table 5). The DNA aneu-
ploid leukoplakias were located at the FOM (n = 2) and lateral
tongue (n = 1). When the location of the lesions was divided be-
tween high-risk (FOM and tongue) versus low-risk (remaining),
DNA aneuploid lesions occurred statistically signiﬁcantly more of-
ten at the high-risk locations (p = 0.03). All DNA aneuploid lesions
were homogeneous. Two patients with DNA aneuploid lesions
were smoker, one was a non-smoker. Two lesions were small
(L1), while one lesion was L2. The DNA aneuploid leukoplakia in
the non-smoker was homogeneous, L1 and located at the lateral
tongue. There were no statistically signiﬁcant differences between
DNA aneuploid and DNA diploid lesions with regard to gender
(p = 0.52), smoking habit (p = 0.83) and alcohol consumption
(p = 0.52), homogeneity (p = 0.22), size (p = 0.85) or type of biopsy
(p = 0.70).Relation between clinicopathological parameters and ploidy measured
by image cytometry (ICM-DNA)
Of the DNA aneuploid lesions as determined by ICM-DNA
(n = 19) eight showed no dysplasia (P0), six were P1 and ﬁve were
P2 (Table 5). In total, 55% of the dysplastic leukoplakias and 46%
of the whole patient group were DNA aneuploid using ICM-DNA.
Although there was no statistically signiﬁcant difference in dyspla-
sia between DNA diploid and DNA aneuploid lesions (p = 0.14),
there was a trend of more severe dysplasia in DNA aneuploid le-
sions (Table 5). There were no statistically signiﬁcant differences
between DNA aneuploid and DNA diploid lesions with regard to
gender (p = 0.68), smoking habit (p = 0.32) and alcohol consump-
tion (p = 0.47), homogeneity (p = 0.49), location (p = 0.26), size
(p = 0.57) or type of biopsy (p = 0.68).Relation between clinicopathological parameters and dysplasia
In this study, 20/41 (50%) leukoplakias showed epithelial dys-
plasia, of which six cases showed severe dysplasia (P2) (Table 5).
Dysplasia (both P1 and P2) in leukoplakia was more often observed
at the high-risk sites (tongue and FOM) than in low-risk sites
(p = 0.02). There was no relation between dysplasia and gender
(p = 0.61), age (p = 0.75), smoking habit (p = 0.61), alcohol con-
sumption (p = 0.44), homogeneity (p = 0.08), or size of the lesion
(p = 0.75).
Table 5
Histopathological grading and DNA ploidy in 41 patients with oral leukoplakia.
FCM-DNA ICM-DNA
Diploid Aneuploid Diploid Aneuploid
Dysplasia P0 21 0 13 8
P1 11 3 8 6
P2 6 0 1 5
E.R.E.A. Brouns et al. / Oral Oncology 48 (2012) 636–640 639Malignant transformation
In two out of 41 patients, two males, an OSCC developed in the
leukoplakia during follow-up. The age of the patients at the time of
OSCC diagnosis was 59 and 67 years, respectively. Both were
smokers and only one of them used regular alcohol. Malignant
transformation occurred 9 and 77 months after the initial biopsy
was taken. The annual malignant transformation rate in this study
is 0.6%. Both patients had multiple sites of leukoplakia. Leukoplakia
was small (L1) in one and large (L3) in the other. The small lesion
was severely dysplastic (P2), while the large lesion was non dys-
plastic (P0). Both leukoplakias were DNA diploid in FCM-DNA,
but DNA aneuploid using ICM-DNA (DNA-index 1.24 and 1.32).
The number of patients with malignant transformation in this co-
hort is too small and the length of follow-up may have been too
short to allow statistical analysis.Discussion and conclusions
In the present study, 41 patients with oral leukoplakia and ploi-
dy determination were included in the period between 2003 and
2010. There have been much more patients with an oral leukopla-
kia observed in this period, but not always a biopsy was taken.
It is questionable whether the histopathological ﬁndings in an
incisional biopsy from a leukoplakia are representative of the entire
lesion27; possibly, this also applies for theDNAploidymeasurement.
There is a big difference in the number of DNA aneuploid lesions
as being determined with different techniques, viz. FCM-DNA and
ICM-DNA. This may be explained by the use of different prepara-
tion techniques.14 Another explanation might be that DNA aneu-
ploid peaks detected by ICM-DNA are not seen in FCM-DNA
when the number of aneuploid epithelial cells is only small or
when large numbers of stromal and inﬂammatory cells are pres-
ent.14 On the other hand, there was one case of DNA aneuploidy as-
sessed with FCM-DNA, which was DNA diploid with ICM-DNA.
Possibly, false positive aneuploid lesions detected by FCM-DNA
may be the result of clustering nuclei, unlike ICM-DNA, in which
technique this clustering is excluded during the visual
inspection.14
In the present study, statistically signiﬁcant relations were
found between DNA aneuploidy determined with FCM-DNA and
dysplasia. DNA aneuploid lesions assessed with FCM-DNA, oc-
curred statistically signiﬁcantly more often at high-risk locations.
The latter ﬁnding is in agreement with another recent study.28
There were no statistically signiﬁcant outcomes with DNA ploidy,
determined with both FCM-DNA and ICM-DNA, and any patient
factor. In contrast, another recent study observed that the mean
percentage of DNA aneuploid nuclei was statistically signiﬁcant
higher in smoking than in non-smoking patients habits.29
In the literature, the prevalence of DNA aneuploidy in non dys-
plastic and dysplastic lesions varies.16–18,30–32 This can be due to
the use of different sources of material, e.g. fresh frozen versus par-
afﬁn embedded tissue, different methods to prepare cytospins and
different ways to interpret the DNA histograms. Moreover, in some
studies only dysplastic lesions have been examined.It should be noted that in the present study, both leukoplakias
that progressed to an OSCC were DNA diploid with FCM-DNA,
but DNA aneuploid with ICM-DNA, suggesting that the use of im-
age cytometry is a more sensitive and clinically relevant parameter
than using ﬂow cytometry. Unfortunately however, there were not
enough patients with progression to cancer to determine the pos-
sible relation between DNA ploidy (FCM-DNA and ICM-DNA) and
malignant transformation. Although the exact role of DNA aneu-
ploidy with regard to malignant transformation is still unknown,
DNA aneuploidy should still be considered as a marker for malig-
nancy.12–17Conﬂict of interest statement
None declared.
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